Neurocrine Biosciences expands crinecerfont trials to infants
Neurocrine Biosciences has launched a Phase 2 clinical study evaluating the safety and tolerability of crinecerfont in children aged 3 months to under 4 years diagnosed with classic congenital adrenal hyperplasia, a move aimed at addressing a critical gap in treatment for the youngest patients suffering from the rare genetic condition.